As for the primary therapy outcome, complete response (CR) patients had lower MTF1 expression than non-CR patients in BLCA, DLBC, and LGG, while in HNSC and prostate adenocarcinoma (PRAD), the results were reversed (Fig. 2C, Supplementary Fig. S1C). Here, MTF1 is linked to bladder transitional cell carcinoma.